NEW YORK – Transplant diagnostics company CareDx said on Wednesday after the close of the market that its preliminary third quarter revenues rose an estimated 57 percent year over year.
For the three months ended Sept. 30, revenues are expected to be approximately $53 million, up from $33.8 million in Q3 2019. Analysts are expecting revenues of $44.7 million for the quarter.
Testing revenues for the quarter are expected to be approximately $45.2 million, up from $28.2 million in the year-ago period. CareDx said it returned approximately 21,800 total AlloSure and AlloMap patient results during the quarter. Product revenues are expected to be $5.4 million, up from $4.2 million in Q3 2019. Digital & other revenues are expected to be $2.4 million, compared to $1.4 million in the year-ago quarter.
"Our strong third quarter performance was driven by this dedication and our commitment to lead in advancing transplantation, underscored by our surveillance solutions, AlloSure and AlloMap," CareDx Chairman and CEO Peter Maag said in a statement.